Thierry Facon

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1295602/publications.pdf

Version: 2024-02-01

94	16,492	81743	43802
papers	citations	39 h-index	91 g-index

96	96	96	10803
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma. New England Journal of Medicine, 2005, 352, 2487-2498.	13.9	2,356
2	Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. Journal of Clinical Oncology, 2015, 33, 2863-2869.	0.8	1,525
3	Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine, 2007, 357, 2123-2132.	13.9	1,365
4	Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma. New England Journal of Medicine, 2012, 366, 1782-1791.	13.9	1,022
5	Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood, 2011, 117, 4691-4695.	0.6	849
6	Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99â€“06): a randomised trial. Lancet, The, 2007, 370, 1209-1218.	6.3	820
7	Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nature Communications, 2014, 5, 2997.	5.8	741
8	Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma. New England Journal of Medicine, 2014, 371, 906-917.	13.9	697
9	Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. New England Journal of Medicine, 2019, 380, 2104-2115.	13.9	684
10	Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet, The, 2019, 394, 29-38.	6.3	665
11	Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood, 2015, 125, 2068-2074.	0.6	586
12	Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood, 2002, 99, 731-735.	0.6	531
13	Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood, 2017, 130, 2401-2409.	0.6	403
14	Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood, 2018, 132, 2456-2464.	0.6	301
15	Prospective Evaluation of Magnetic Resonance Imaging and [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study. Journal of Clinical Oncology, 2017, 35, 2911-2918.	0.8	247
16	Frontline therapy of multiple myeloma. Blood, 2015, 125, 3076-3084.	0.6	244
17	VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial. Blood, 2016, 127, 2569-2574.	0.6	224
18	Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood, 2018, 131, 301-310.	0.6	216

#	Article	IF	Citations
19	Prognostic role of circulating exosomal miRNAs in multiple myeloma. Blood, 2017, 129, 2429-2436.	0.6	214
20	Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet, The, 2020, 396, 1563-1573.	6.3	188
21	Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet, The, 2021, 397, 2361-2371.	6.3	177
22	Combination of International Scoring System 3, High Lactate Dehydrogenase, and t(4;14) and/or del(17p) Identifies Patients With Multiple Myeloma (MM) Treated With Front-Line Autologous Stem-Cell Transplantation at High Risk of Early MM Progressionâ€“Related Death. Journal of Clinical Oncology, 2014, 32, 2173-2180.	0.8	150
23	Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2021, 22, 1582-1596.	5.1	141
24	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncology, The, 2021, 22, e105-e118.	5.1	136
25	A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. Leukemia, 2020, 34, 224-233.	3.3	122
26	Labial salivary gland biopsy is a reliable test for the diagnosis of primary and secondary amyloidosis. a prospective clinical and immunohistologic study in 59 patients. Arthritis and Rheumatism, 1993, 36, 691-697.	6.7	96
27	Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du MyÃ©lome. Journal of Clinical Oncology, 2016, 34, 2125-2132.	0.8	91
28	High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridization. , 1999, 24, 9-15.		84
29	Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience. Blood, 2015, 125, 2095-2100.	0.6	82
30	Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. Leukemia, 2021, 35, 31-44.	3.3	79
31	Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide. Haematologica, 2015, 100, 826-833.	1.7	76
32	Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial. Journal of Clinical Oncology, 2016, 34, 3609-3617.	0.8	71
33	Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. Leukemia, 2018, 32, 1542-1560.	3.3	68
34	Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors. JAMA Oncology, 2020, 6, 1759.	3.4	64
35	P53 deletion is not a frequent event in multiple myeloma. British Journal of Haematology, 1999, 106, 717-719.	1.2	62
36	The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma. Nature Communications, 2021, 12, 293.	5.8	54

#	Article	IF	Citations
37	A predictive model for risk of early gradeâ€‰â‰¥â€‰3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial. Leukemia, 2018, 32, 1404-1413.	3.3	53
38	del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma. Blood, 2021, 137, 1192-1195.	0.6	48
39	Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma. Blood, 2015, 125, 3100-3104.	0.6	47
40	Deregulation and Targeting of TP53 Pathway in Multiple Myeloma. Frontiers in Oncology, 2018, 8, 665.	1.3	47
41	Defining the vulnerable patient with myelomaâ€”a frailty position paper of the European Myeloma Network. Leukemia, 2020, 34, 2285-2294.	3.3	45
42	Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. HemaSphere, 2021, 5, e528.	1.2	45
43	Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk. Haematologica, 2020, 105, e480-483.	1.7	42
44	Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA. Leukemia, 2022, 36, 1066-1077.	3.3	39
45	Current state and next-generation CAR-T cells in multiple myeloma. Blood Reviews, 2022, 54, 100929.	2.8	38
46	BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma. Clinical Cancer Research, 2020, 26, 2422-2432.	3.2	37
47	Bendamustine is effective in Tâ€Cell prolymphocytic leukaemia. British Journal of Haematology, 2015, 168, 916-919.	1.2	36
48	Frontline Therapy with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Induction Followed By Autologous Stem Cell Transplantation, Krd Consolidation and Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma (NDMM) Patients: Primary Results of the Intergroupe Francophone Du MyÃ©Lome (IFM) Krd Phase II Study. Blood, 2016, 128, 1142-1142.	0.6	36
49	Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients. Haematologica, 2014, 99, 1236-1238.	1.7	35
50	Effective anti-BCMA retreatment in multiple myeloma. Blood Advances, 2021, 5, 3016-3020.	2.5	30
51	Updated Analysis of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): The Phase 3 Maia Study. Blood, 2020, 136, 24-26.	0.6	29
52	Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis. Haematologica, 2021, 106, 1182-1187.	1.7	27
53	Subgroup analysis of ICARIAâ€MM study in relapsed/refractory multiple myeloma patients with highâ€risk cytogenetics. British Journal of Haematology, 2021, 194, 120-131.	1.2	27
54	Daratumumab is effective in the relapsed or refractory systemic lightâ€chain amyloidosis but associated with high infection burden in a frail realâ€life population. British Journal of Haematology, 2020, 188, e24-e27.	1.2	26

#	Article	IF	Citations
55	Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration. Clinical Cancer Research, 2021, 27, 5195-5212.	3.2	26
56	Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: Updated Analysis of Maia. Blood, 2019, 134, 1875-1875.	0.6	26
57	Daratumumabâ€lenalidomideâ€dexamethasone vs standardâ€ofâ€care regimens: Efficacy in transplantâ€ineligible untreated myeloma. American Journal of Hematology, 2020, 95, 1486-1494.	2.0	25
58	The Prognostic Impact of Complete Remission (CR) Plus Very Good Partial Remission (VGPR) in a Double-Transplantation Program for Newly Diagnosed Multiple Myeloma (MM). Combined Results of the IFM 99 Trials.. Blood, 2006, 108, 3077-3077.	0.6	20
59	Phase I Study of AVE1642 Anti IGF-1R Monoclonal Antibody in Patients with Advanced Multiple Myeloma.. Blood, 2007, 110, 1166-1166.	0.6	19
60	Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014â€04 (Etoile du Nord) trial. British Journal of Haematology, 2019, 187, 319-327.	1.2	18
61	Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma. Blood Advances, 2020, 4, 5449-5459.	2.5	17
62	Bortezomib, lenalidomide, and dexamethasone (VRd) Â± daratumumab (DARA) in patients (pts) with newly diagnosed multiple myeloma (NDMM) for whom transplant is not planned as initial therapy: A multicenter, randomized, phase III study (CEPHEUS).. Journal of Clinical Oncology, 2019, 37, TPS8056-TPS8056.	0.8	17
63	Onceâ€weekly (70 mg/m²) vs twiceâ€weekly (56 mg/m²) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPIONâ€1 trials. Cancer Medicine, 2020, 9, 2989-2996.	1.3	16
64	Effect of age and frailty on the efficacy and tolerability of onceâ€weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. American Journal of Hematology, 2021, 96, 708-718.	2.0	16
65	Continuous treatment with lenalidomide and lowâ€dose dexamethasone in transplantâ€ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the <scp>FIRST</scp> trial. British Journal of Haematology, 2017, 176, 743-749.	1.2	14
66	A Frailty Scale Predicts Outcomes of Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone on the First Trial. Blood, 2015, 126, 4239-4239.	0.6	13
67	The genomic landscape of plasma cells in systemic light chain amyloidosis. Blood, 2018, 132, 2775-2777.	0.6	12
68	Improved survival in multiple myeloma during the 2005â€“2009 and 2010â€“2014 periods. Leukemia, 2021, 35, 3600-3603.	3.3	11
69	Synergistic effects of low-dose belantamab mafodotin in combination with a gamma-secretase inhibitor (nirogacestat) in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-5 study.. Journal of Clinical Oncology, 2022, 40, 8019-8019.	0.8	11
70	Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: <scp>ICARIAâ€MM</scp> subgroup analysis. American Journal of Hematology, 2021, 96, E423-E427.	2.0	10
71	Efficacy of Daratumumab in Combination with Standard of Care Regimens in Lenalidomide-Exposed or -Refractory Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Analysis of the Castor, Pollux, and MMY1001 Studies. Blood, 2018, 132, 3288-3288.	0.6	10
72	Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis. Advances in Therapy, 2022, 39, 1976-1992.	1.3	10

#	Article	IF	Citations
73	Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study. BMC Cancer, 2021, 21, 993.	1.1	8
74	A Comprehensive Analysis of Cytogenetic Abnormalities in Myeloma: Results of the FISH Analysis of 1000 Patients Enrolled in the IFM99 Trials.. Blood, 2005, 106, 622-622.	0.6	8
75	Treatment approach for the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a European hematologist. Hematology American Society of Hematology Education Program, 2018, 2018, 83-87.	0.9	7
76	Frontline Therapy for Patients with Multiple Myeloma not Eligible for Stem Cell Transplantation. Hematology/Oncology Clinics of North America, 2014, 28, 829-838.	0.9	6
77	Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study. Blood, 2021, 138, 3793-3793.	0.6	6
78	Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis. Hematological Oncology, 2022, 40, 1020-1029.	0.8	6
79	Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis.. Journal of Clinical Oncology, 2021, 39, 8026-8026.	0.8	5
80	Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis.. Journal of Clinical Oncology, 2021, 39, 8042-8042.	0.8	5
81	Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma. Blood Cancer Journal, 2021, 11, 55.	2.8	4
82	Association of Morbid Progression With Overall Survival Among Patients With Multiple Myeloma: Validation of the Progression-free Survival Endpoint. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 345-354.e4.	0.2	4
83	First-Line Use of Daratumumab, Lenalidomide, and Dexamethasone Confers Survival Benefit Compared with Second-Line Use of Daratumumab-Based Regimens in Transplant-Ineligible Patients with Multiple Myeloma: Analysis of Different Clinical Scenarios. Blood, 2021, 138, 118-118.	0.6	4
84	Evaluation of the Relevance of Surgery in Patients with Multiple Myeloma Harboring Symptomatic Spinal Involvement: A Retrospective Case Series. World Neurosurgery, 2018, 114, e356-e365.	0.7	3
85	A matching-adjusted indirect treatment comparison (MAIC) of daratumumabâ€“bortezomibâ€“melphalanâ€“prednisone (D-VMP) versus lenalidomideâ€“dexamethasone continuous (Rd continuous), lenalidomideâ€“dexamethasone 18 months (Rd 18), and melphalanâ€“prednisoneâ€“thalidomide (MPT). Leukemia and Lymphoma, 2020, 61, 714-720.	0.6	3
86	Case Report: Two Cases of Cryptosporidiosis in Heavily Pretreated Patients With Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e545-e547.	0.2	3
87	Efficacy of Isatuximab with Pomalidomide and Dexamethasone in Elderly Patients with Relapsed/Refractory Multiple Myeloma: Icaria-MM Subgroup Analysis. Blood, 2019, 134, 1893-1893.	0.6	3
88	Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis. Haematologica, 2022, 107, 774-775.	1.7	2
89	A Matching-Adjusted Indirect Treatment Comparison of Daratumumab-Bortezomib-Melphalan-Prednisone Versus Lenalidomide-Dexamethasone Continuous, Lenalidomide-Dexamethasone 18 Months, and Melphalan-Prednisone-Thalidomide. Blood, 2018, 132, 3551-3551.	0.6	1
90	Effectiveness of Daratumumab in Combination with Lenalidomide and Dexamethasone (DRd) Vs. Common Standard-of-Care Regimens in Patients with Non-Transplant Newly Diagnosed Multiple Myeloma (NDMM). Blood, 2019, 134, 1830-1830.	0.6	1

#	Article	IF	Citations
91	The Relationship between Baseline Biomarkers and Efficacy of Isatuximab in Combination with Pomalidomide and Dexamethasone in RRMM: Insights from Phase 1 and Phase 3 Studies. Blood, 2019, 134, 3179-3179.	0.6	1
92	High-Resolution Genomic Profiles Identify Novel Genes and/or Chromosomal Regions with Prognostic and Oncogenic Significance in Myeloma Patients.. Blood, 2007, 110, 657-657.	0.6	0
93	GuÃ©rison du myÃ©lome multiple : un objectif envisageable Ã court terme ?. Bulletin De L'Academie Nationale De Medecine, 2018, 202, 953-961.	0.0	0
94	Mutations and Copy Number Changes Predict Progression from Smoldering Myeloma to Symptomatic Myeloma in the Era of Novel IMWG Criteria. Blood, 2018, 132, 4456-4456.	0.6	0